dilTIAZem HCl Injection Recalled Due to Sterility Assurance Failure
SterRx is recalling dilTIAZem HCl 125 mg per 125 mL injectable solution nationwide due to lack of assurance of sterility. The recall affects 24,300 bags distributed across the United States.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA has classified this as a Class II recall. Lack of sterility assurance in an injectable pharmaceutical product presents a serious risk of infection or other adverse effects in patients receiving intravenous medication, warranting a Severe classification.
Plain-English summary
SterRx, LLC is recalling dilTIAZem HCl 125 mg per 125 mL (1 mg per mL) in 0.7% Sodium Chloride Injection, an intravenous medication, due to lack of assurance of sterility. A total of 24,300 bags have been distributed nationwide.
The affected lots are: S21164/BTV (3-Dec-21), S21191/BUU (18-Dec-21), S21197/BUZ (31-Dec-21), S21220/BVV (13-Jan-22), S21271/BX0 (27-Jan-22), S21272/BXP (28-Jan-22), S21299/BYP (18-Feb-22), and S21300/BYQ (19-Feb-22). The product is identified by NDC 70324-976-01.
Healthcare providers and patients who have received this medication should contact their healthcare provider to discuss potential risks and next steps. Patients should not stop taking prescribed medications without consulting their healthcare provider.
The recalled product
- Product
- dilTIAZem HCl 125 mg per 125 mL (1 mg per mL) in 0.7% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY, 12903, NDC 70324-976-01.
- Manufacturer
- SterRx, LLC
- Category
- Drug — Injectable / Intravenous
- Hazard
- sterility-failure
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lots S21164/BTV
- 3-Dec-21
- S21191/BUU
- 18-DEC-21
- S21197/BUZ
- 31-Dec-21
- S21220/BVV
- 13-Jan-22
- S21271/BX0
- 27-Jan-22
- S21272/BXP
- 28-Jan-22
- S21299/BYP
- 18-Fev-22
- S21300/BYQ
- 19-Feb-22
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateEstradiol Gel Packets Recalled for Empty or Partially Full Containers
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27